Merck KGaA: latest news - GoINPHARMA
Monday, 10 December 2018 - 3:18

Merck KGaA

Green light in EU to sale of Merck KGaA’s OTC division to P&G

Germany-based Merck KGaA has obtained by the European Union competition watchdogs the authorization to sell its OTC division to P&G for €3.4bn. The transaction was announced as early as last April. Specifically, the German company will sell a part of…

Analyzing German’s Merck KGaA oncology pipeline

The Germany-based economic and financial daily Handelsblatt today has published a long and detailed analysis of Merck KGaA’s oncology pipeline. The Darmastadt-based group’s leading product is Bavencio (avelumab), a immunotherapy co-developed with Pfizer through an agreement signed in 2014, which…

M&A of Consumer Health units at a stalemate

The market provides with a wide range of opportunities those companies that want to enhance their Consumer Health portfolio through acquisitions. Assets are currently on sale by Germany-based Merck KGaA, intending to dismiss its Consumer Health arm for €4bn, and…

Negative 2017 revenues for Germany-based Merck KGaA

Darmastadt-based chemical-pharmaceutical group Merck KGaA has reported today its 2017 financial results, which are below expectations, and shares (Frankfurt) have immediately declined by over 4%. The most severely hit arm in 2017 was Performance Materials, whose EBITDA dropped by 11%…

Face to face comparison Teva and Merck KGaA

Israel-based daily Globes yesterday published an article comparing Merck KGaA’s and Teva’s strategies.  The analysis focuses on the events from 2012 onwards, as Merck Serono–a subsidiary of Merck’s–closed down its oncology R&D center in Geneva, dismissing 580 employees. The decision…

Merck KGaA opens R&D center to develop nanotechnologies in Jerusalem

German’s Merck KGaA this week has opened its technology innovation laboratory at its subsidiary Qlight Nanotech in Jerusalem. The laboratory, in the Hebrew University campus, will be used to develop new technologies and materials. Qlight Nanotech is a spin-off of…

Perrigo ready to acquire Merck KGaA’s Consumer Health unit

Perrigo is reported to be a serious bidder to Merck KGaA’s Consumer Health unit, with an estimated value of at least €4.7bn. Perrigo has a cash reserve of approximately $776m (Q3 2017), thus it needs to secure a line of…

Merck KGaA’s Marcus Kuhnert named CFO of the month

The German economic and financial daily Handelsblatt published today a long article about Marcus Kuhnert, Merck KGaA’s CFO since 2014, naming him CFO of the month. Marcus Kuhnert, 49, born in Chicago, but grown up north of Frankfurt, has a…

Merck KGaA presents strategy to investors, yet shares significantly drop

Germany-based Merck KGaA has presented this week its new strategy to investors. On the occasion, the management has confirmed the current year guidance, despite market conditions have considerably worsened for the Darmstadt-headquartered company. The management lowered the guidance in August,…

New multiple sclerosis therapy by Merck approved in Europe

The German-language press today gave extensive coverage to the marketing approval in Europe to Cladribine, a brand-new multiple sclerosis therapy developed by Germany-based Merck KGaA. Cladribine is the first oral treatment ever commercialized for multiple sclerosis, a condition affecting 2.3…

Employees of Germany’ s Merck afraid of sale of Chemicals division

The top management of Germany-based Merck announced a long time ago it plans to split the group into three independent units (Pharma, Chemicals and Laboratory instruments) raises serious concern among labor representatives, afraid that this plan will lead to selling…

Investors welcome new structure of Merck KGaA

The decision announced some days ago by Germany’s Merck KGaA, of splitting the group into three parts, adopting an holding structure, was welcomed by investors. The decision foreruns an easy carve-out of any of the divisions, which could lead to…

All-German M&A agreement between Fresenius and Merck KGaA

German’s Merck KGaA sold its biosimilars business to Fresenius. As part of the agreement, Fresenius will make an initial €170m payment, followed by additional payments of up to €500m, based on successful completion of precise milestones. Moreover, if the products…

Notable victory for Merck KGaA: FDA approves Bavencio (skin cancer)

Merck KGaA’s anti-PD-L1 immunotherapy Bavencio was approved by FDA for the primary treatment of Merkel cell carcinoma, a rare type of skin cancer for which there was still no FDA-approved therapy to date. Bavencio, developed in partnership with US-based Pfizer,…

Record results from Merck KGaA (2016)

German chemical-pharmaceutical group Merck KGaA reported today its 2016 financial results, which were beyond analysts’ expectations. Revenue increased by 17% to a record €15bn, with a €4.5bn EBITDA (+23,7 % vs 2015). Debt decreased by €1bn and EPS rose 27.5%…

Merck KGaA enters the Food&Beverage business by acquiring BioControl System

Merck KgaA today announced it has acquired US-based BioControl Systems (Bellevue, Washington). BioControl is a company with approximately 100 employees. In 2015, it generated revenue of $34m. The acquisition allows Merck to enter the food&beverage industry. Indeed, the acquiree develops…

Evaluations ten years after Merck acquired Serono

Ten years have now passed since when Merck acquired competitor Serono for €10.6bn. The takeover was seen as an emergency solution for Merck, which was steadily losing market share. 6 years later, in 2012, Merck closed down Serono’s Geneva branch…

Evotec and Merck to cooperate in developing new gene therapies

The two Germany-based groups Evotec and Merck announced they will cooperate in carrying out research for new therapies and, importantly, in developing the CRISPR technology, which allows to treat and modify genes and can lead to develop new treatments—including antitumorals….

Merck, first cuts following integration of Sigma Aldrich

Merck KGaA seeks to take advantages of the synergies from the takeover of US-based Sigma Aldrich, which cost over $17bn. The management, indeed, decided to close down the European branch of the US group, in St. Gallen, as of 2017….

Big Pharma: the companies with drugs and vaccines essential for public health

Access to Medicine Foundation performed an analysis to identify the pharmaceutical companies which have essential drugs and vaccines on the market. The report was prepared by comparing the pharmaceutical companies’ product portfolios with the Model Essential Medicines List (EML), compiled…